Odonate Therapeutics, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2020-03-06: Study NCT04312282; Company role Lead sponsor; Phase Phase 1; Status Terminated.
- 2019-07-09: Study NCT03952325; Company role Lead sponsor; Phase Phase 2; Status Terminated.
- 2019-02-05: Study NCT03858972; Company role Lead sponsor; Phase Phase 2; Status Terminated.
- 2017-12-21: Study NCT03326674; Company role Lead sponsor; Phase Phase 3; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2020-03-06 | NCT04312282 The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors | Lead sponsor | Phase 1 | Terminated | Advanced Solid Tumors | 93 | 2021-06-15 |
| 2019-07-09 | NCT03952325 Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | Lead sponsor | Phase 2 | Terminated | Breast Cancer | 294 | 2021-06-23 |
| 2019-02-05 | NCT03858972 Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC | Lead sponsor | Phase 2 | Terminated | Breast Cancer | 152 | 2021-06-11 |
| 2017-12-21 | NCT03326674 Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC | Lead sponsor | Phase 3 | Terminated | Breast Cancer | 685 | 2021-06-28 |